GUARDANT HEALTH CL. A Logo
US40131M1099
A2N5RY
GH

GUARDANT HEALTH CL. A

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 185,04 € (+39,49%). La mediana è 181,94 € (+37,16%).

Acquista
  30
Mantieni
  0
Vendi
  1

Discussioni nella community

  • Hinzufügen von Aktie nicht möglich

    kajdo kajdo I in Schnack

    0 12

  • Guardant Health reports record quarter, raises full-year guidance and stock nears all-time high

    Guardant Health reported a record quarter with revenue up 44% to $335 million and raised its full-year guidance to $1.34–$1.36 billion. Growth was driven by core oncology revenues and the expanding Shield colorectal screening program, while a new lab process is expected to cut the cost per Shield test by about 15% by year-end. The company aims for cash-flow breakeven by the end of 2027; in the near term it remains loss-making with an expected cash burn of roughly $200 million in 2026. Chart‑wise, the stock broke out of a sideways consolidation and is trading just below its previous all-time high. » Altro su finanzen.net


  • Guardant Health: Shield screening scales strongly, CDx business gains from new approvals

    Guardant Health said at the Morgan Stanley conference it posted more than 40% revenue growth in Q2, an oncology volume increase of over 60% and Shield growth of more than 250%. According to management, Shield covers 80% of eligible individuals (about 94 million people) and cost per test is expected to fall from just over $400 to roughly $350 by year-end, with a long-term target of $200. Guardant360 Liquid CDx received an expanded FDA approval as the sole companion diagnostic for Camizestrant; the company expects ADLT status for Guardant360 in H1 2025 and sees further growth potential from combined screening, profiling and MRD applications despite near-term pricing and reimbursement pressure. » Altro su de.investing.com


  • Guardant Health: EviCore to reimburse Shield blood test for colorectal cancer screening starting 2027

    Guardant Health announced that EviCore by Evernorth has added the Shield blood test for colorectal cancer early detection to its clinical guidelines effective January 1, 2027. Reimbursement will apply to insured individuals aged 45 and older at average risk, expanding the covered population to about 94 million people across 23 states. Shield is FDA-cleared for primary screening using methylation partitioning cell-free DNA technology; a positive result requires follow-up colonoscopy. The test is included in American Cancer Society and National Comprehensive Cancer Network guidelines and has already been used more than 200,000 times. » Altro su de.investing.com


  • Guardant Health scales Shield blood test for colorectal cancer and expands market opportunities

    Guardant Health's FDA-approved and reimbursed Shield blood test provides a painless method for colorectal cancer screening and opens up a mass market. Despite ongoing spending on sales and research, rising test volumes, falling lab costs and partnerships with pharma companies are driving scale-up. The company plans to gradually extend the offering to additional cancer types. » Altro su finanzen.net


  • Artisan adds Guardant Health, cites leadership in liquid biopsies and rising Shield adoption

    Artisan Mid Cap Fund added Guardant Health during Q2 2026, highlighting the company's market-leading liquid biopsy diagnostics and expanding portfolio across oncology and cancer screening. Guardant reported another strong quarter driven by higher testing volumes and accelerating adoption of its Shield colorectal screening test, prompting management to raise full-year revenue guidance. The fund believes Guardant is well positioned to benefit from growing precision oncology adoption, AI-enabled diagnostics, an expanding data repository and improving reimbursement and product catalysts. » Altro su finance.yahoo.com

Nel 2022, GUARDANT HEALTH CL. A ha già distribuito 0,11 € di dividendi. L'ultimo pagamento è avvenuto a giugno 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, GUARDANT HEALTH CL. A ha registrato ricavi pari a 318,69 Mln € e un utile netto di -109,79 Mln €
(EUR) settembre 2026
YoY
Ricavi 318,69 Mln 41,02%
Utile lordo 208,49 Mln 42,57%
Utile netto -109,79 Mln 38,95%
EBITDA -99,32 Mln 41,72%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
17,86 Mld €
Numero di azioni
135,29 Mln
Massimo/minimo a 52 settimane
173,80 € - 67,82 €
Dividendi No
Beta
1,66
Rapporto P/E
-39,44
Rapporto PEG
2,98
Rapporto P/B
-70,71
Rapporto P/S
15,35

Profilo aziendale

Guardant Health, Inc., una società di oncologia di precisione, fornisce test ematici, set di dati e servizi di analisi negli Stati Uniti e a livello internazionale. La società offre Guardant360, Guardant360 LDT, Guardant360 CDx e GuardantOMNI, test di biopsia liquida per il cancro in stadio avanzato; e GuardantINFORM, una piattaforma di ricerca in silico che comprende un set di dati clinico-genomici di biopsia liquida di pazienti affetti da cancro avanzato. È inoltre in fase di sviluppo del test LUNAR-2 per la diagnosi precoce del cancro del colon-retto in individui asintomatici idonei; e GuardantConnect, una soluzione software integrata per clienti clinici e biofarmaceutici che desiderano collegare i pazienti sottoposti al test Guardant360 con alterazioni utilizzabili a fini terapeutici e potenzialmente pertinenti a sperimentazioni cliniche. Inoltre, la società offre il test Guardant Reveal per la selezione del trattamento neoadiuvante e adiuvante in pazienti con cancro in fase iniziale; il prodotto di genotipizzazione tissutale Guardant360; e Guardant-19 per l'uso nella rilevazione del nuovo coronavirus. Inoltre, offre servizi di sviluppo, tra cui lo sviluppo di test companion diagnostici e l'approvazione normativa, l'allestimento di studi clinici, il monitoraggio e la manutenzione, lo sviluppo e il supporto dei test, e servizi correlati alla fornitura di kit ad aziende biofarmaceutiche e istituti medici. La società è stata costituita nel 2011 ed ha sede a Redwood City, California.

Nome
GUARDANT HEALTH CL. A
CEO
Helmy Eltoukhy
Sede centrale Palo Alto, ca
Stati Uniti
Sito web
Settore
Sanità
Industria
Attrezzature e forniture sanitarie
Quotazione in borsa
04/10/2018
Dipendenti 2498

Simboli di borsa

Borsa Simbolo
NASDAQ
GH
Frankfurt
5GH.F
Düsseldorf
5GH.DU
München
5GH.MU
🍪

Parqet  usa i cookie. Scopri di più